Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Evolocumab lowers LDL cholesterol by more than 50% (NEJM) |
![]() |
![]() |
NEJM: Among the 901 patients included in the primary analysis, the overall least-squares mean (+/-SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0 +/-2.1% (P<0.001). |